• About Us
    • About Us
    • Corporate Strategy
    • Our Vision and Values
    • Research & Development
    • Operations
    • Business Development
    • Awards and Grants
  • Announcements
  • Our Team
    • Management Team
    • Scientific Team
    • Scientific Advisory Board
  • Portfolio
    • Our Portfolio
    • Lupuzor™ & Lupus
    • Autoimmunity
    • Metabolism
    • Anti-infectives
    • Cancer
  • Investors
    • Investor Relations
    • AIM Rule 26 Information
    • Euronext Growth
    • Regulatory News
    • Market Commentary
    • Share Price
    • Analyst Research
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Interviews
    • Professional Advisers
    • Email Alerts
  • Media
    • Events and Conferences
    • Media Room
    • Interviews
    • Scientific Publications
  • Contact Us
Archives
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
February 29, 2012

ImmuPharma PLC Appoints Head of Investor Relations

Read More
November 03, 2011

ImmuPharma’s Lupuzor™ given approval to start phase III and Fast Track designation by the FDA

Read More
October 21, 2011

ImmuPharma regains Lupuzor rights from Cephalon due to Teva merger

Read More
  • 1
  • …
  • 13
  • 14
  • 15
Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2020 | All rights reserved

Cookies

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the Cookie Policy